Webinar Technology

RECAST: Deciphering immuno-oncology: Targeting innate immunity in cancer

This webinar is brought to you by the Science/AAAS Custom Publishing Office

RECAST: Deciphering immuno-oncology: Targeting innate immunity in cancer

27 November 2018

7:00 a.m. ET

Register to watch recording


This webinar includes a rebroadcast of the presentations from a previous event, followed by a new live Q&A.

While targeting T cells has proven to be a technically successful treatment protocol for most cancer immunotherapies, only a fraction of cancer patients respond to these interventions. Of late there has been a surge of interest in investigating the relatively underexplored innate immune system as a possible tool for therapeutic intervention. Innate immune effector cells, including natural killer cells, macrophages, and dendritic cells, have been shown to interact with cancers and inhibit their progression. Dissecting the molecular details of these interactions will aid in identifying cancer-derived intrinsic factors that can be exploited to be develop effective immunotherapy regimens. Our speakers will provide examples of how innate immunity pathways are involved in fighting cancer, and how these pathways might be co-opted to generate new treatments.

During the webinar, viewers will:

  • Learn how dendritic cells maintain a local antitumor immune response within the tumor microenvironment
  • Gain an understanding of how therapeutic interventions targeting dendritic cells can promote tumor immunity and enhance the efficacy of cancer therapy
  • Hear how inflammatory pathways, commonly upregulated in human malignancies, represent major determinants of tumor fate
  • Have their questions answered during the live broadcast!

You can also view part 1, part 3 and Part 4 of this series.

This webinar will last for approximately 60 minutes.

Speaker bios

Stefani Spranger, Ph.D.

Massachusetts Institute of Technology
Cambridge, MA

Dr. Spranger pursued her scientific training at the Ludwig Maximilian University of Munich in Munich, Germany, first receiving her undergraduate degree in biology and then completing a Ph.D. in immunology. She then joined the University of Chicago as a postdoctoral fellow, supported by the German Research Foundation as well as the Cancer Research Institute, later moving to her current position as assistant professor at the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology. Her work seeks to elucidate the mechanisms and pathways underlying the interaction between the immune system and cancer using mouse models that recapitulate the coevolution of tumor progression and the antitumor immune response. This research aims to shed light on new or improved immunotherapies for human cancers.

Santiago Zelenay, Ph.D.

Cancer Research UK Manchester Institute
Manchester, UK

Dr. Zelenay obtained his undergraduate degree in biology from the University of Buenos Aires in 2002. As a student he worked on DNA vaccines in the laboratory of Juan Fló. He received his Ph.D. in immunology at the Gulbenkian Institute of Science in Portugal, where he studied regulatory T cells, working with Jocelyne Demengeot and António Coutinho. In 2008, he joined the group of Caetano Reis e Sousa at the Cancer Research UK (CRUK) London Research Institute and later joined the Francis Crick Institute, where he was awarded Marie Curie and EMBO long-term postdoctoral fellowships to investigate innate immune receptors and signaling pathways that trigger dendritic cell activation and drive T-cell responses against viruses or tumors. In 2015, Dr. Zelenay joined the CRUK Manchester Institute as a junior group leader to form the Cancer Inflammation and Immunity Group. His group focuses on understanding the underlying mechanisms that mediate cancer-inhibitory versus tumor-promoting inflammation, with the goal of designing new therapies for cancer patients. In 2017, he received the CRUK Future Leaders in Cancer Research Prize.

Sean Sanders, Ph.D.

Washington, DC

Dr. Sanders did his undergraduate training at the University of Cape Town, South Africa, and his Ph.D. at the University of Cambridge, UK, supported by the Wellcome Trust. Following postdoctoral training at the National Institutes of Health and Georgetown University, Dr. Sanders joined TranXenoGen, a startup biotechnology company in Massachusetts working on avian transgenics. Pursuing his parallel passion for writing and editing, Dr. Sanders joined BioTechniques as an editor, before joining Science/AAAS in 2006. Currently Dr. Sanders is the Senior Editor for Custom Publishing for the journal Science and Program Director for Outreach.

Sponsored by

Get webinar alerts

For more information on upcoming webinars, recorded sessions and more, sign up for webinar alerts.

Sign up here